These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34207212)

  • 1. Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Areson C; van der Straten A; Johnson LM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
    Schlesinger E; Johengen D; Luecke E; Rothrock G; McGowan I; van der Straten A; Desai T
    Pharm Res; 2016 Jul; 33(7):1649-56. PubMed ID: 26975357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP).
    Johnson LM; Krovi SA; Li L; Girouard N; Demkovich ZR; Myers D; Creelman B; van der Straten A
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31277461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones.
    Li L; Gatto GJ; Brand RM; Krovi SA; Cottrell ML; Norton C; van der Straten A; Johnson LM
    J Control Release; 2021 Dec; 340():188-199. PubMed ID: 34678316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Johnson LM; Krovi SA; Demkovich ZR; van der Straten A
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33167509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
    Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate.
    Simpson SM; Widanapathirana L; Su JT; Sung S; Watrous D; Qiu J; Pearson E; Evanoff A; Karunakaran D; Chacon JE; Kiser PF
    Pharm Res; 2020 Apr; 37(4):83. PubMed ID: 32296951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
    Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
    Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
    J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques.
    Gatto GJ; Krovi A; Li L; Massud I; Holder A; Gary J; Mills P; Mitchell J; Luecke E; Demkovich ZR; Heneine W; García-Lerma JG; Marzinke MA; Brand RM; Dobard CW; Johnson LM; Van Der Straten A
    Front Pharmacol; 2022; 13():923954. PubMed ID: 35928266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biodegradable blend matrices for controlled drug release.
    Lin M; Meng S; Zhong W; Li Z; Du Q; Tomasik P
    J Pharm Sci; 2008 Oct; 97(10):4240-8. PubMed ID: 18271038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.
    Chua CYX; Jain P; Ballerini A; Bruno G; Hood RL; Gupte M; Gao S; Di Trani N; Susnjar A; Shelton K; Bushman LR; Folci M; Filgueira CS; Marzinke MA; Anderson PL; Hu M; Nehete P; Arduino RC; Sastry JK; Grattoni A
    J Control Release; 2018 Sep; 286():315-325. PubMed ID: 30092254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
    Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
    Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
    Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA
    Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
    Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
    Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
    Massud I; Krovi A; Nishiura K; Ruone S; Li L; Holder A; Gary J; Mills P; Mitchell J; Khalil G; Pan Y; Luecke E; Gatto G; Heneine W; García-Lerma JG; Johnson L; van der Straten A; Dobard C
    J Antimicrob Chemother; 2022 Oct; 77(11):2964-2971. PubMed ID: 35913838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.